Shares of Sana Biotechnology Inc. (SANA) touched a 52-week high of $12 during intraday trading Friday, thanks to the company setting a strong foundation in three therapeutic areas with significant unmet needs - blood cancers, B-cell mediated autoimmune diseases, and type 1 diabetes.
The company's lead drug candidate is SC291, a hypoimmune (HIP), allogeneic, CD19-directed CAR T cell therapy.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com